Combination therapy with a dipeptidyl peptidase-4 inhibitor (DPP-4i) and a proton pump inhibitor (PPI) raises endogenous levels of GLP-1 and gastrin, respectively, and restores pancreatic β-cell mass and normoglycemia in nonobese diabetic (NOD) mice with autoimmune diabetes. The aim of this study was to determine whether a DPP-4i and PPI combination could increase β-cell mass in the adult human pancreas. Pancreatic cells from adult human pancreas donors were implanted in NOD-severe combined immunodeficient (NODscid) mice and the mice were treated with a DPP-4i and a PPI for 16 weeks. Human grafts were examined for insulin content and insulin-stained cells. Graft β-cell function was assessed by intravenous glucose tolerance tests (IVGTT) and by glucose control in human cell-engrafted mice treated with streptozotocin (STZ) to delete mouse pancreatic β-cells. Plasma GLP-1 and gastrin levels were raised to two-to threefold in DPP-4i-and PPI-treated mice. Insulin content and insulin-stained cells in human pancreatic cell grafts were increased 9-to 13-fold in DPP-4i and PPI-treated mice and insulin-stained cells were colocalized with pancreatic exocrine duct cells. Plasma human C-peptide responses to IVGTT were significantly higher and STZinduced hyperglycemia was more completely prevented in DPP-4i-and PPI-treated mice with grafts than in vehicle-treated mice with grafts. In conclusion, DPP-4i and PPI combination therapy raises endogenous levels of GLP-1 and gastrin and greatly expands the functional β-cell mass in adult human pancreatic cells implanted in immunodeficient mice, largely from pancreatic duct cells. This suggests that a DPP-4i and PPI combination treatment may provide a pharmacologic therapy to correct the β-cell deficit in type 1 diabetes.
INTRODUCTION
late β-cell regeneration in streptozotion (STZ)-induced diabetic rats (11). Gastrin is another gastrointestinal peptide reported to Many pancreatic β-cell growth factors have been identified, one of the most promising being glucagon-induce β-cell neogenesis from pancreatic exocrine duct cells in rodents (12, 18) . The combination of GLP-1 and like peptide-1 (GLP-1), a peptide secreted from intestinal endocrine L-cells in response to nutrient ingestion.
gastrin was found to increase the β-cell mass in adult human pancreatic cells (14) and restore normoglycemia GLP-1 is rapidly cleaved and inactivated in vivo by dipeptidyl peptidase-4 (DPP-4), a ubiquitous serine prote-in nonobese diabetic (NOD) mice (15) . In addition, combination therapy with a DPP-4i and a proton pump ase. DPP-4 inhibitors (DPP-4i) raise circulating levels of active GLP-1 and thus increase and maintain effective inhibitor (PPI) raised circulating levels of GLP-1 and gastrin respectively and reversed diabetes in NOD mice concentrations of this peptide reaching target tissues (4). Studies in humans with type 2 diabetes have shown that (13) . Here, we report that combination therapy with a DPP-4i and a PPI raised endogenous levels of GLP-1 DPP-4i therapy improves glucose tolerance (1). In addition, DPP-4i treatments can preserve pancreatic β-cell and gastrin in immunodeficient mice implanted with adult human pancreatic cells, and this combination ther-mass in animal models of type 2 diabetes (9) and stimu-1344 SUAREZ-PINZON AND RABINOVITCH apy significantly expanded the functional β-cell mass in chemical and immunofluorescence studies and from six mice of each group for assay of insulin content. the human pancreatic cell grafts.
In the second study, NOD-scid mice were divided MATERIALS AND METHODS into three groups of 6 mice/group. The first group was sham implanted. The other two groups were implanted Human Pancreatic Cells with human pancreatic cells (2 × 10 6 ) obtained from two Human pancreases were obtained, with informed different human organ donors, and cells from each panconsent of relatives, from brain-dead adult organ donors.
creas were distributed to three mice in each of the two Tissue procurement and experimental protocols were apgroups (n = 6 mice/group). One group was treated with proved by the human ethics committee of the University DPP-4i and PPI and the other with vehicles for 16 weeks of Alberta Hospitals. Pancreatic islets were isolated as as in the first study. All mice were then fasted and treatpreviously described (6) and islet preparations with low ments stopped for 24-28 h before intravenous glucose endocrine cell purity (<20% dithizone-stained cells) tolerance tests (IVGTT) were carried out by IV injection were used in this study. Islets were dissociated into sinof 1.5 g/kg glucose. Blood was collected for glucose and gle cells and small clumps (≤5 cells) as previously dehuman C-peptide levels before and 10, 30, and 120 min scribed (7). Cells from the nine donor pancreases used after glucose injection. in this study contained 16 ± 2% β-cells, 6 ± 1% α-cells,
In the third study, NOD-scid mice were divided into 20 ± 3% exocrine duct cells, and 31 ± 4% acinar cells three groups. The first group of mice (n = 10) was sham (see Immunohistochemical Studies).
implanted. The other two groups were implanted with human pancreatic cells (2 × 10 6 ) obtained from four dif-Cell Implants in Mice ferent human organ donors, and cells from each pan-NOD-severe combined immunodeficient (NOD-scid) creas were distributed to three mice in each of the two female mice, age 6-8 weeks, purchased from Jackson groups (n = 12 mice/group). One group was treated with Laboratory (Bar Harbor, ME), were used as recipients DPP-4i and PPI and the other with vehicles for 16 weeks of the human pancreatic cell implants. The mice were as in the first study. Treatments were stopped and all housed and fed under specific pathogen-free conditions mice were treated with streptozotocin (STZ, Sigmain a biocontainment hood and were cared for according Aldrich, St. Louis, Mo) 70 mg/kg given by IP injection to the guidelines of the Canadian Council on Animal once daily for 6 days to destroy β-cells in mouse pan-Care. Pancreatic cell implants were placed under the left creas without damaging β-cells in the human pancreatic renal capsule of the mice according to a previously decell grafts (2). Blood glucose concentrations were meascribed procedure (17). sured every 3-5 days for 34 days after STZ administration, and then the left kidneys with the human pancreatic Experimental Studies cell grafts were removed from the anesthetized mice. The mice recovered and blood glucose concentrations In the first study, NOD-scid mice were divided into four groups. One group of mice (n = 6) was sham im-were measured daily until they exceeded 25 mmol/L; then the mice were killed. planted. The other three groups of mice were implanted with human pancreatic cells (2 × 10 6 ) obtained from Blood Glucose three different human organ donors, and cells from each pancreas were distributed to four mice in each of the Blood glucose concentrations were measured using a blood glucose meter and test strips (Ascencia Elite, three groups (n = 12 mice/group). The human pancreatic cell grafts with a portion of underlying kidney were re-Bayer, Etobicoke, ON, Canada). moved 1 day after implantation in the first group of Peptide Hormone Assays mice, and the mice were killed. The other two groups of mice with human pancreatic cell grafts were treated for Active GLP-1(7-36) amide in mouse plasma was measured using an enzyme linked immunosorbent assay 16 weeks with either i) a DPP-4i, sitagliptin (Merck Frosst, Canada) 100 mg/kg given by oral gavage once (ELISA) electrochemiluminescence assay (Meso Scale Discovery, Gaithersburg, MD). Serum gastrin was mea-daily and a PPI, pantoprazole (Nycomed, Oakville, Canada) 40 mg/kg given by SC injection twice daily or ii) sured using a radioimmunoassay (RIA) for the major circulating forms of mouse gastrin (MP Biomedicals, the DPP-4i vehicle, methylcellulose in H 2 O and the PPI vehicle, PBS. After 16 weeks, blood was collected 8-10
Orangeburg, NY). Plasma human C-peptide was measured using a RIA with no cross-reactivity to mouse C-h after treatments for assays of GLP-1 and gastrin. Grafts with a portion of underlying kidney were re-peptide (Linco Research, St. Charles, MO). Pancreatic insulin content was measured in ethanolic extracts of the moved from six mice of each group for immunohisto-human pancreatic cell grafts using an electrochemilum-using Axioplan 4.1 multidimensional acquisition software (Carl Zeiss Canada, Toronto, Canada). inescence immunoassay and analyzer (Roche, Mannheim, Germany).
Statistical Analyses Immunohistochemical Studies
Data are expressed as means ± SE. The Mann-Whitney rank sum test was used to compare two groups, and Composition of the human pancreatic cells before implantation in mice was determined according to a pre-a one-way ANOVA followed by Dunnett's multiple comparison tests was used when more than two groups viously described method (14) . Briefly, β-cells were identified by staining with a guinea pig anti-insulin anti-were compared. A value of p < 0.05 was considered significant. Analyses were done using InStat 3 Windows body, α-cells by staining with a rabbit anti-human glucagon antibody, exocrine duct cells by staining with a (Graph Pad, Software, San Diego, CA). mouse anti-human CK19 antibody, and acinar cells by RESULTS staining with a rabbit anti-α-amylase antibody. Primary antibodies were followed by secondary biotinylated anti-Plasma GLP-1 and serum gastrin levels were elevated two-to threefold in NOD-scid mice implanted with hu-bodies and streptavidin enzyme conjugates and substrate kits. The β-cell mass in human pancreatic cell grafts re-man pancreatic cells and treated with DPP-4i and PPI compared with levels in mice implanted with pancreatic moved from the mice was determined by point-counting morphometry on insulin-immunostained sections of the cells and treated with vehicles, or mice not implanted or treated (Fig. 1a, b ). Immunohistochemical examination grafts according to a previously described method (15) . Briefly, five sections from each graft were scanned us-of the human pancreatic cell grafts revealed a striking expansion in the size of the graft in mice treated for 16 ing a Scanscope Imagescope system (Aperio Technologies, Vista, CA) at a magnification 40×. The digital im-weeks with DPP-4i and PPI (Fig. 1e ) compared with grafts initially implanted ( Fig. 1c ) and grafts in mice ages were analyzed with Scanscope software and the number of positive signals (insulin-stained cells) as a treated for 16 weeks with vehicles ( Fig. 1d ). Importantly, the area of insulin-stained cells (mm 2 × 10 −3 ) was percent of the total (positive plus negative) signals representing the total graft tissue area scanned was deter-significantly increased in human pancreatic cell grafts in mice treated with DPP-4i and PPI (60.0 ± 6.3) compared mined by Positive Pixel Count Algorithm (Aperio). The β-cell area per graft was calculated by multiplying the with grafts initially implanted (4.6 ± 0.4) and grafts in mice treated with vehicles (11.3 ± 1.7) ( Fig. 1f ). Also, percent of insulin-positive signals by the total area of the graft tissue scanned.
insulin content (µg/graft) was significantly increased in human pancreatic cell grafts in DPP-4i-and PPI-treated Immunofluorescence Studies mice (15.2 ± 1.8) compared with grafts initially implanted (1.6 ± 0.2) and grafts in mice treated with vehi-Tissue samples were fixed overnight in Zinc Formal-Fixx (Fisher Scientific, Ottawa, Canada) and then pro-cles (2.5 ± 0.2) (Fig. 1g ). The area of the human pancreatic cell grafts occupied by cells stained for the CK-cessed and embedded in paraffin, after which 3-µm sections were cut and placed on histobond slides (Fisher 19 duct cell marker (mm 2 × 10 −3 ) was also greatly increased in the human pancreatic cell grafts in DPP-4i-Scientific). The sections were rehydrated to water, followed by the quenching of endogenous peroxide by a and PPI-treated mice (57.2 ± 10.0) compared with grafts initially implanted (5.4 ± 1.1) and grafts in mice solution of 20% hydrogen peroxide in methanol for 6 min. Blocking was performed with 20% normal goat se-treated with vehicles (2.8 ± 0.5). Immunofluorescence study of the human pancreatic cell grafts in DPP-4i-rum (Jackson ImmunoResearch Laboratories, West Grove, PA) for 15 min at room temperature. Primary and PPI-treated mice revealed that essentially all insulin-stained cells were colocalized to cells stained for antibody concentrations were as follows: 1:1000 guinea pig anti-insulin (Dako Cytomation, Missisauga, Can-the pancreatic exocrine duct cell marker CA19-9 (Fig.  2) . Plasma human C-peptide basal levels and responses ada), 1:50 mouse anti-CA19-9 (AbD Serotec Raleigh, NC). The primary antibody incubation was 1 h at room to IVGTT were significantly higher in DPP-4i-and PPI-treated mice with human pancreatic cell grafts temperature, followed by three washes in PBS. This was followed by secondary antibody staining for 30 min at compared with vehicle-treated mice with grafts ( Fig.  3b ) and blood glucose clearance was more rapid room temperature using goat anti-guinea pig AlexaFluor 488 and goat anti-mouse AlexaFluor 594 (Invitrogen, (Fig. 3a) .
To determine the impact of insulin secretion from the Burlington, Canada). Slides were then cover slipped using Prolong Gold antifade plus DAPI (to stain nuclei), human pancreatic cell grafts on blood glucose levels independent of insulin secretion from host mouse pancre-and visualized on an Axioplan 2 fluorescent microscope Figure 1. Effects of dipeptidyl peptidase-4 inhibitor (DPP-4i) and proton pump inhibitor (PPI) in nonobese diabetic severe combined immunodeficient (NOD-scid) mice implanted with human pancreatic cell grafts. Plasma active glucagon-like peptide-1 (GLP-1) (a) and serum gastrin (b) levels in mice that received grafts and were treated for 16 weeks with DPP-4i and PPI (black bars) or with vehicles (shaded bars) and in mice sham-implanted and not treated (white bars). Photomicrographs of histological sections of human pancreatic cells implanted under the renal capsule of NOD-scid mice show few insulin-containing cells (stained dark brown) in grafts at day 1 (c), more insulin-containing cells in grafts of vehicle-treated mice at 16 weeks (d), and many more insulincontaining cells in grafts of DPP-4i-and PPI-treated mice at 16 weeks (e). Insulin-stained cells (f) and insulin contents (g) in the grafts at day 1 (striped bars), and at 16 weeks after treatment with vehicles (shaded bars), or DPP-4i and PPI (black bars). Mean ± SE values are shown for six mice in each group. **p < 0.01 for DPP-4i and PPI versus vehicle-treated mice. atic β-cells, we treated the mice with STZ to destroy treatment in mice with human pancreatic cell grafts and treated with DPP-4i and PPI. Severe hyperglycemia rap-mouse pancreatic β-cells without affecting human βcells in the grafts (2). STZ treatment rapidly induced idly developed when the human pancreatic cell grafts were removed from mice that had received either vehi-severe hyperglycemia (>25 mmol/L) and death in mice that had not been implanted with human pancreatic cell cle or DPP-4i and PPI treatments, indicating that blood glucose control in the STZ-treated mice depended on grafts, whereas mice that had received grafts were relatively protected from diabetes development (Fig. 4) .
functional β-cells in the human pancreatic cell grafts, and that this was significantly better in mice that had Blood glucose levels rose to 10-15 mmol/L after STZ treatment in mice with human pancreatic cell grafts and been treated with DPP-4i and PPI than with vehicles ( Fig. 4) . treated with vehicles, but to only 7-8 mmol/L after STZ 
DISCUSSION
Hyperglycemia in both type 1 and type 2 diabetes results from a relative or absolute deficit in the pancreatic β-cell mass; therefore, β-cell regeneration is an area under active investigation. Clinical interpretation of βcell regenerative therapies is limited; however, because days. Blood glucose levels are shown after STZ administration and after removal of the grafts at day 40 (arrow). Mean ± SE min) IV injection of 1.5 g/kg glucose for six mice in each group. *p < 0.05, **p < 0.01 for DPP-4i and PPI versus vehi-values are shown for 10-12 mice in each group. *p < 0.05, **p < 0.01 for DPP-4i and PPI versus vehicle-treated mice. cle-treated mice. these studies have been almost exclusively carried out required because reversal of autoimmune diabetes in NOD mice is accompanied by effects of GLP-1 and gas-in rodent models of diabetes or under in vitro conditions.
In the present study, we found that the DPP-4i and trin on immunoregulatory cytokines (15) were increased 9-to 13-fold over 16 weeks. The elevations of circulating levels of GLP-1 and gastrin resulting REFERENCES from DPP-4i and PPI treatments were likely responsible
